Protocol core needle biopsy and histological chronic allograft damage index as surrogate endpoint for long-term graft survival

Transplantation Proceedings

Volumn 36, Issue 1, 2004, Pages 89-91

  Hayry, P ^a   Paavonen, T ^b   Taskinen, E ^b   Tomlanovich, E ^b   Mathew, T ^b   Navarro, M ^b   Ramos, E ^b   Hooftman, L ^b   Vamvakopoulos, J ^b   Aavik, E ^b   Yilmaz, S ^b  

^a UNIVERSITY OF HELSINKI   (Finland)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

CREATININE;

CONFERENCE PAPER; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DISEASE MARKER; DISEASE SEVERITY; GRAFT SURVIVAL; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; KIDNEY ALLOGRAFT; KIDNEY GRAFT REJECTION; KIDNEY TRANSPLANTATION; MAJOR CLINICAL STUDY; NEEDLE BIOPSY; POSTOPERATIVE PERIOD; PREDICTION; PRIORITY JOURNAL;

EID: 0842303345     PISSN: 00411345     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.transproceed.2003.11.006     Document Type: Conference Paper

References (15)

1. Hunsicker L.G., Bennett L.E. Design of trials of methods to reduce late renal allograft loss the price of success . Kidney Int Suppl. 52:1995;S120.
2. Myllärniemi M., Calderon Ramirez L., Lemström K., et al. Inhibition of platelet-derived growth factor receptor tyrosine kinase inhibits vascular smooth muscle cell migration and proliferation. FASEB J. 11:1997;1119.
3. Sihvola R., Koskinen P., Myllärniemi M., et al. Prevention of cardiac allograft arteriosclerosis by protein tyrosine kinase inhibitor selective for platelet-derived growth factor receptor. Circulation. 99:1999;2295.
4. Mäkelä S., Savolainen H., Aavik E., et al. Differentiation between vasculoprotective and uterotrophic effects of estrogen via targeting to estrogen receptor beta. PNAS. 96:1999;7077.
5. Aavik E., Luoto N.M., Petrov L., et al. Elimination of vascular fibrointimal hyperplasia by somatostatin receptor 1.4 selective agonist. FASEB J. 16:2002;724.
6. Yilmaz S., Taskinen E., Paavonen T., et al. Chronic rejection of rat renal allograft. I. Histological differentiation between chronic rejection and cyclosporin nephrotoxicity. Transpl Int. 5:1992;85.
7. Isoniemi H., Taskinen E., Hayry P. Histological chronic allograft damage index accurately predicts chronic renal allograft rejection. Transplantation. 58:1994;1195.
8. Kasiske B.L., Kalil R.S., Lee H.S., et al. Histopathologic findings associated with a chronic, progressive decline in renal allograft function. Kidney Int. 40:1991;514.
9. Dimeny E., Wahlberg J., Larsson E., et al. Can histopathological findings in early renal allograft biopsies identify patients at risk for chronic vascular rejection? Clin Transplant. 9:1995;79.
10. Yilmaz S., Tomlanovich S., Mathew T., et al. Protocol core needle biopsy and histological chronic allograft damage index (CAD) as surrogate end-point for long-term graft survival in multicenter studies. Journal of American Society of Nephrology. 14:2003;773.
11. Sollinger H.W. Mycophenolate mofetil for the prevention of acute rejection in primary cadaveric renal allograft recipients. U.S. Renal Transplant Mycophenolate Mofetil Study Group. Transplantation. 60:1995;225.
12. Mycophenolate mofetil in cadaveric renal transplantation. Am J Kidney Dis. 34:1999;296.
13. A blinded, randomized clinical trial of mycophenolate mofetil for the prevention of acute rejection in cadaveric renal transplantation. Transplantation. 6:1996;1029.
14. Mathew T.H. A blinded, long-term, randomized multicenter study of mycophenolate mofetil in cadaveric renal transplantation results at three years . Tricontinental Mycophenolate Mofetil Renal Transplantation Study Group. Transplantation. 65:1998;1450.
15. Hayry P., Yilmaz S., Taskinen E., et al. Intermediate efficacy endpoints for chronic kidney allograft rejection implications of protocol core biopsy for early registration of new agents . Lieberman R., Mukherjee A. Principles of Drug Development in Transplantation and Autoimmunity. 1996;557 R.G. Landes Company, Austin, Texas.